HitGen offers comprehensive solutions for the development of oligonucleotide therapeutics, covering the entire process from research and development to production.
The efficient delivery of nucleic acids to target organs is critical for achieving therapeutic efficacy. Compared to antisense oligonucleotides (ASOs), siRNA faces more significant challenges in traversing cell membranes due to its inherent negative charge, necessitating the use of highly efficient delivery vehicles. OBT platform at HitGen developed delivery systems for both liver and extrahepatic organs, which had already been validated via in vitro and in vivo experiments.
Target organ | Reference | HitGen | Validated by |
Liver | L96 | equivalent | |
CNS | Alnylam C16 | Better | In vitro & in vivo |
Customized project: collaborating in milestone-based manner | |||
川公网安备 51012202000492号
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information
